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a b s t r a c t
Relaxin is a polypeptide hormone that triggers multiple signaling pathways through its receptor RXFP1
(relaxin family peptide receptor 1). Many of relaxin’s functions, including vascular and antiﬁbrotic effects,
are similar to those induced by activation of PPAR␥. In this study, we tested the hypothesis that relaxin
signaling through RXFP1 would activate PPAR␥ activity. In cells overexpressing RXFP1 (HEK-RXFP1),
relaxin increased transcriptional activity through a PPAR response element (PPRE) in a concentrationdependent manner. In cells lacking RXFP1, relaxin had no effect. Relaxin increased both the baseline
activity and the response to the PPAR␥ agonists rosiglitazone and 15d-PGJ2 , but not to agonists of PPAR␣ or
PPAR␦. In HEK-RXFP1 cells infected with adenovirus expressing PPAR␥, relaxin increased transcriptional
activity through PPRE, and this effect was blocked with an adenovirus expressing a dominant-negative
PPAR␥. Knockdown of PPAR␥ using siRNA resulted in a decrease in the response to both relaxin and
rosiglitazone. Both relaxin and rosiglitazone increased expression of the PPAR␥ target genes CD36 and
LXR␣ in HEK-RXFP1 and in THP-1 cells naturally expressing RXFP1. Relaxin did not increase PPAR␥ mRNA
or protein levels. Treatment of cells with GW9662, an inhibitor of PPAR␥ ligand binding, effectively
blocked rosiglitazone-induced PPAR␥ activation, but had no effect on relaxin activation of PPAR␥. These
results suggest that relaxin activates PPAR␥ activity, and increases the overall response in the presence
of PPAR␥ agonists. This activation is dependent on the presence of RXFP1. Furthermore, relaxin activates
PPAR␥ via a ligand-independent mechanism. These studies represent the ﬁrst report that relaxin can
activate the transcriptional activity of PPAR␥.
Published by Elsevier Ireland Ltd.

1. Introduction
Relaxin is a polypeptide hormone of the insulin superfamily, which also includes the relaxin-like peptides relaxin-3 and
insulin-like peptide-3 (InsL3) (Sherwood, 2004). Despite considerable structural similarity to insulin, relaxin does not bind to the
insulin receptors and has no insulin-like glucocoregulatory effects.
The identiﬁcation of a relaxin receptor proved elusive, which hampered progress in relaxin research for many years, until Hsu et al.
identiﬁed two relaxin receptors in 2002. Somewhat surprisingly,
unlike the receptors for insulin and insulin-like growth factor I,
which signal through tyrosine kinase receptors, the leucine-rich G
protein-coupled receptors 7 and 8 (LGR7 and LGR8) were identi-
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ﬁed as relaxin receptors (Hsu et al., 2002). These receptors are now
known as relaxin family peptide receptor (RXFP) 1 and 2, respectively (Bathgate et al., 2006). Although relaxin will bind to and
activate both receptors in vitro, the evidence thus far suggests that
only RXFP1 is activated by relaxin in vivo, and therefore RXFP1 is
considered to be the cognate relaxin receptor, while RXFP2 is the
InsL3 receptor.
Activation of RXFP1 stimulates adenylyl cyclase and increases
cAMP through a complex, biphasic mechanism (Halls et al., 2006;
Nguyen et al., 2003). Initially, RXFP1 couples to G␣s , resulting in
rapid increase in cAMP (Halls et al., 2006). This is followed by coupling to G␣o and a transient decrease in cAMP production, then
ﬁnally a delayed and sustained increase in cAMP mediated through
coupling to G␣i and activation of phosphoinositide 3 -kinase and
protein kinase C through G␤/␥ subunits (Halls et al., 2006; Nguyen
et al., 2003). In addition to stimulation of cAMP, a number of other
pathways can also be triggered by relaxin signaling. Relaxin effects
in a number of tissues are mediated by stimulation of nitric oxide
synthase and increased nitric oxide production (Baccari and Bani,
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2008). In some cells, relaxin can activate the extracellular signalrelated kinase 1 and 2 (ERK1/2) pathway, in a process that may
involve the nuclear factor NF-B (Dschietzig et al., 2003; Ho et al.,
2007; Zhang et al., 2002; Mookerjee et al., 2009). Additional studies
have suggested that relaxin can activate a tyrosine kinase pathway in some cells (Anand-Ivell et al., 2007; Bartsch et al., 2001;
Palejwala et al., 2001). There is also a report that relaxin can activate the glucocorticoid receptor through a mechanism that may
be independent of RXFP1 (Dschietzig et al., 2005). Therefore, the
accumulating evidence suggests that relaxin signals through highly
diverse and complex mechanisms.
The traditional functions attributed to relaxin are related
to pregnancy, where its functions include inhibition of uterine
contraction, and inducement of cervical growth and softening
(Sherwood, 2004). However, recent studies have revealed that
relaxin has many nonreproductive functions. It has been long
known that relaxin has antiﬁbrotic effects related to its ability to
regulate the expression and degradation of extracellular matrix
components. In ﬁbroblasts and myoﬁbroblasts, relaxin inhibits
transforming growth factor beta (TGF-␤)-induced collagen production and promotes matrix degradation, and decreases ﬁbrillar
collagen in experimental models of dermal, pulmonary, renal, and
hepatic ﬁbrosis (Samuel, 2005). This property was strongly supported by studies of the relaxin-null mouse. These mice developed
age-related ﬁbrosis in a number of tissues including the lung, skin,
heart, and kidney (Samuel et al., 2005), suggesting a role for relaxin
in the treatment of ﬁbrosis, and in the prevention of the development of age-related ﬁbrosis. In addition, relaxin exhibits properties
related to the control of cardiovascular functions. Relaxin promotes
vasodilation and angiogenesis, protects against ischemic damage,
and displays anti-inﬂammatory properties, largely through nitric
oxide-dependent pathways (Bani, 2008; Baccari and Bani, 2008).
Therefore, in addition to its reproductive role, relaxin is an important modulator of a number of physiological processes outside of
pregnancy. Many of these nonreproductive functions of relaxin
are similar to those regulated by peroxisome proliferator-activated
receptor gamma (PPAR␥).
The peroxisome proliferator-activated receptors (PPARs) are
nuclear receptors that heterodimerize with the retinoid X receptors (RXR) to induce transcription of target genes (Evans et al.,
2004). Three major PPARs have been identiﬁed to date. PPAR␣,
the earliest identiﬁed form, is involved in peroxisome proliferation and lipid utilization. Less is known about PPAR␦ (also known
as PPAR␤), but its main functions appear to be in fatty acid utilization. The third form, PPAR␥ is a major regulator of adipogenesis
(Tontonoz and Spiegelman, 2008). Agonists of PPAR␥, such as the
antidiabetic thiazolidinedione drugs, promote lipid storage in adipose tissue, decrease serum lipid levels, and regulate adipokine
secretion from the adipose tissue, and increase insulin responsiveness in the liver and muscle (Tontonoz and Spiegelman, 2008).
In addition, PPAR␥ agonists have antiﬁbrotic properties in the
skin, heart, kidney, lung and liver (Calkin et al., 2006; Genovese
et al., 2005; Iglarz et al., 2003; Wu et al., 2009; Galli et al.,
2002), and induce anti-inﬂammatory, cardiovascular, and antiﬁbrotic effects (Tontonoz and Spiegelman, 2008; Varga and Nagy,
2008).
Because relaxin and PPAR␥ share a number of biological effects,
it is possible that they possess common signaling pathways. Relaxin
stimulates the production of cAMP and nitric oxide, both regulators of PPAR␥ activity (Lazennec et al., 2000; Ptasinska et al., 2007;
Watanabe et al., 2003). Therefore, it is possible that activation of
PPAR␥ may be one mechanism for the antiﬁbrotic effects of relaxin.
We hypothesized that relaxin activation of RXFP1 would result in
increased PPAR␥ activity. To explore this possibility, we sought to
determine the effect of relaxin on the levels and activity of PPAR␥
in cells expressing RXFP1.

2. Materials and methods
2.1. Materials
Highly puriﬁed porcine relaxin (Sherwood and O’Byrne, 1974) was provided by
O. David Sherwood (University of Illinois Urbana-Champaign). The RXFP1 expression
plasmid (Hsu et al., 2000) was provided by Aaron Hsueh (Stanford University). The
PPAR luciferase reporter plasmid ACO-PPRE (Jiang et al., 1998) was provided by
Brian Seed (Harvard University). Adenoviruses expressing wild-type and mutant
PPAR␥ and ␤-galactosidase (Park et al., 2003) were provided by J. Larry Jameson
(Northwestern University). Human relaxin-3 (H3 relaxin) and insulin-like peptide
3 (InsL3) were from Phoenix Pharmaceuticals. Rosiglitazone, GW0742, GW9662,
and 15-12,14-deoxy prostaglandin J2 (15d-PGJ2 ) were from Cayman Chemical.
WY-14,643 was from Sigma Chemical.
2.2. Production of cell lines stably expressing RXFP1
To generate cells stably expressing RXFP1, a plasmid encoding LGR7/RXFP1
containing a FLAG epitope (Hsu et al., 2000) was transfected into HEK-293T cells
(American Type Culture Collection) using Fugene-6 according to the manufacturer’s
instructions. Cells stably expressing the FLAG-RXFP1 were selected using zeocin
(Invitrogen) at 400 g/mL, and individual clones were isolated and screened for
RXFP1 expression using an in-cell Western blot procedure. Cells grown on poly-llysine coated 96-well plates were ﬁxed in 4% paraformaldehyde for 20 min, then
washed and solubilized in PBS containing 0.1% Triton X-100 for 5 min for a total of
5 washes. After blocking in Odyssey block (Li-Cor) for 2 h, wells were incubated
with either M2 anti-FLAG antibody (Sigma) or an antibody to a control protein
(rabbit anti-insulin-degrading enzyme, Millipore) at a 1:1000 dilution in Odyssey
block overnight at 4 ◦ C. After washing 5 times with PBS containing 0.1% Tween-20
for 5 min each, the cells were incubated in the dark with IRDye-680 labeled goat
anti-rabbit or IRDye-800 labeled goat anti-mouse secondary antibodies for 1 h at
room temperature. After 5 washes with PBS containing 0.1% Tween-20 and one ﬁnal
PBS wash, ﬂuorescence was measured in an Odyssey infrared ﬂuorescence scanner
(Li-Cor). The clones with the highest FLAG content relative to the control protein
were selected and expanded. The cells were then screened for relaxin responsivity (cAMP production), and a ﬁnal clone (HEK-RXFP1) was selected and used for all
studies.
2.3. Reporter and cAMP assays
PPAR activation was monitored using a dual-luciferase reporter assay. Cells were
transfected with a plasmid (ACO-PPRE) containing three copies of the acyl-CoA oxidase PPRE element upstream of the ﬁreﬂy luciferase gene (Jiang et al., 1998), and
a plasmid containing the renilla luciferase gene under the control of the thymidine kinase promoter (pRL-TK, Promega) to control for transfection efﬁciency and
cell number. After 24 h, cells were treated and incubated for 24 h, and then ﬁreﬂy
and renilla luciferase activities were measured using the Dual-Glo assay (Promega).
For cAMP determinations, cells were treated for 30 min at room temperature, and
cAMP content was determined using the cAMP-Glo assay (Promega) following the
manufacturer’s instructions.
2.4. Overexpression and knockdown of PPAR
To increase expression of PPAR␥, HEK-RXFP1 cells were infected with a total
of 45 ifu of replication-incompetent adenovirus containing the genes for ␤galactosidase (␤-Gal), wild-type PPAR␥, or dominant-negative Leu466Ala-PPAR␥
(Park et al., 2003). After 24 h, cells were transfected with ACO-PPRE and pRLTK plasmids, treated with relaxin or rosiglitazone for 24 h, then subject to the
PPRE luciferase reporter assay as described above. For knockdown of PPAR␥, siRNA
and reporter plasmids were applied to HEK-RXFP1 cells using Nucleofection Kit V
(Amaxa) as directed by the manufacturer. Each nucleofection reaction contained
2 g siRNA (either PPAR␥ siRNA or nontargeting control SMARTpool siRNA, Dharmacon), 1 g ACO-PPRE and 0.1 g pRL-TK. After nucleofection, cells were seeded
onto poly-l-lysine coated 96-well or 24-well plates. After 24 h, cells in 96-well plates
were treated with relaxin or rosiglitazone for 24 h, then subject to the dual-luciferase
assay as described above. Cells in 24-well plates were lysed and knockdown of PPAR␥
was veriﬁed using anti-PPAR␥ (Santa Cruz) and anti-GAPDH (Millipore) primary
antibodies, followed by IR-Dye labeled secondary antibodies (Li-Cor). Fluorescence
was detected using Odyssey infrared ﬂuorescence scanner (Li-Cor).
2.5. Gene expression assays
Cells were treated for 16 h, then total cellular RNA was extracted using the
Purelink kit (Invitrogen). The RNA was reverse transcribed using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems), and then subject to TaqMan
real-time PCR. The gene expression assays (Applied Biosystems) used were PPAR␥
(Hs00234592 m1), CD36 (Hs00169627 m1), LXR␣ (Hs00172885 m1), and 18S rRNA
(Hs99999901 s1). Gene expression was normalized to the level of 18S rRNA within
each sample using the relative CT method.
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Fig. 1. Relaxin activates PPAR activity through RXFP1. Cells expressing RXFP1 (HEK-RXFP1) or without RXFP1 (HEK) were treated with relaxin or related peptides. (A) Cells
transfected with ACO-PPRE and pRL-TK reporter plasmids were treated with the indicated concentrations of relaxin for 24 h, then subject to ﬁreﬂy and renilla luciferase
assays. The data are expressed as the ACO-PPRE luciferase activity relative to that in untreated cells, mean ± S.E.M. (N = 3). (B) HEK-RXFP1 or HEK cells were treated with the
indicated concentrations of relaxin for 30 min, then subject to cAMP quantitation. Data are expressed as the actual cAMP concentration (nM) mean ± S.E.M. of triplicate wells.
(C) Cells were treated with 100 nM relaxin, H3 relaxin or InsL3 for 24 h or 30 min for PPRE luciferase assay (N = 3) or cAMP determination (triplicate wells), respectively.

2.6. Statistical analysis
Curve-ﬁtting and statistical analysis was performed using Prism 5 software
(GraphPad). Differences were analyzed using one-way or two-way analysis of variance as appropriate, with Bonferroni’s post-test. Data are expressed as mean ± S.E.M.
of at least three independent determinations except as indicated in the ﬁgure legends.

3. Results
3.1. Relaxin increases PPAR transcriptional activity in
RXFP1-expressing cells
Activation of PPARs induces binding to peroxisome proliferator response elements (PPRE) in target gene promoters, resulting
in gene transcription. To determine the effect of relaxin on PPAR
activity, a reporter plasmid containing three tandem copies of the
PPRE from acyl-CoA oxidase upstream of the ﬁreﬂy luciferase gene
was used to monitor activation of PPAR. Relaxin treatment of HEKRXFP1 cells resulted in a concentration-dependent increase in PPAR
activity (Fig. 1A). The apparent EC50 was 22.39 pM, with a maximal increase in PPRE transcriptional activity of approximately
two-fold. There was no response in the parental HEK cells (not
expressing RXFP1). Consistent with activation of RXFP1, relaxin
treatment increased cAMP production in HEK-RXFP1 cells, but not
cells lacking RXFP1 (Fig. 1B). The calculated pEC50 value for cAMP
stimulation was 214.7 pM. The effect was speciﬁc to RXFP1 ligands, as both relaxin and the alternative RXFP1 agonist H3 relaxin
(human relaxin-3) induced PPRE transcriptional activity, but the
relaxin-like peptide InsL3, which is the physiological ligand for
RXFP2, and has very low afﬁnity for RXFP1, had no signiﬁcant effect
(Fig. 1C).

PPAR␣ and PPAR␦ to their agonists either alone or in combination
with relaxin make it unlikely that they are the target of the relaxin
effects on the PPRE reporter, while the greater response to PPAR␥
agonists makes it more likely that PPAR␥ is the target of relaxin
signaling.
To conﬁrm that the target of relaxin signaling was PPAR␥,
cells were infected with adenoviruses expressing either wild-type
(wtPPAR␥) or dominant-negative PPAR␥ (dnPPAR␥). The dnPPAR␥
possesses DNA binding activity, but has reduced transcriptional
activity due to preferential binding to corepressors (Park et al.,
2003), and thus can inhibit the wtPPAR␥. Infection with wtPPAR␥
caused an increase in the basal and rosiglitazone-induced PPRE
transcriptional activation (Fig. 3). Relaxin also increased the activation of wtPPAR␥, as well as the residual activity in the presence
of the dnPPAR␥. However, when cells were coinfected with both
wtPPAR␥ and dnPPAR␥, the response to both relaxin and rosiglitazone was greatly suppressed. To more directly identify PPAR␥ as
the target of relaxin signaling, siRNA was used to reduce the expression of PPAR␥. Introduction of PPAR␥ siRNA, but not control siRNA,

3.2. Relaxin activates PPAR
The PPRE reporter plasmid used above is not speciﬁc, and can
be activated by PPAR␣, PPAR␦, or PPAR␥. To explore the potential role of each of the PPARs in the cell model, HEK-RXFP1 cells
were treated with PPAR subtype-speciﬁc agonists, with or without relaxin. Agonists for either PPAR␣ or PPAR␦ (WY-14,643 and
GW0742, respectively) slightly increased the activity of the PPRE
reporter (Fig. 2). The combination of either WY-14,643 or GW0742
with relaxin resulted in PPRE transcriptional activity that did not
differ from relaxin alone. In contrast, agonists of PPAR␥ (rosiglitazone and 15d-PGJ2 ) induced a much greater increase in activation
of the PPRE reporter. Furthermore, the combination of relaxin and
PPAR␥ agonists resulted in an induction of PPRE that was significantly greater than either treatment alone. The low responses of

Fig. 2. Relaxin increases the overall response to PPAR␥ agonists. HEK-RXFP1 cells
were treated for 24 h with or without 1 nM relaxin in the presence or absence of speciﬁc PPAR agonists, then subject to the PPRE luciferase assay. The agonists used were
WY-14,643 (WY, 2 M) for PPAR␣; GW-0742 (GW, 10 nM) for PPAR␦; and rosiglitazone (Rosi, 1 M) or 15-deoxy-12,14-PGJ2 (PGJ2 , 1 M) for PPAR␥. The data are
expressed as the ACO-PPRE luciferase activity relative to that in untreated cells,
mean ± S.E.M. (N = 5). *p < .05 compared to corresponding agonist in the absence of
relaxin; #p < .05 compared to no treatment; †p < .05 compared to either relaxin or
corresponding agonist alone.

242

S. Singh, R.G. Bennett / Molecular and Cellular Endocrinology 315 (2010) 239–245

Fig. 3. Effect of relaxin on wild-type and dominant-negative PPAR␥. HEK-RXFP1
cells were infected with adenoviruses expressing ␤-galactosidase (␤-Gal), wild-type
PPAR␥ (WT), dominant-negative PPAR␥ (DN) or WT:DN at a 1:2.5 ratio. Cells were
then treated with relaxin (1 nM), rosiglitazone (1 M), or vehicle for 24 h, then subject to the PPRE luciferase assay. The data are expressed as the ACO-PPRE luciferase
activity relative to that in uninfected untreated cells. Data are mean ± S.E.M., N = 3.
*p < .001 compared to ␤-Gal; †p < .01 compared to WT.

reduced the level of PPAR␥ protein in HEK-RXFP1 cells (Fig. 4A). Furthermore, in the presence of PPAR␥ siRNA, transcription through
PPRE in response to relaxin or rosiglitazone was reduced, whereas
control siRNA had no effect (Fig. 4B).
To conﬁrm that relaxin activation of PPAR␥ resulted in activation of gene transcription, the ability of relaxin to induce the
expression of PPAR␥ target genes was determined in HEK-RXFP1
cells. Both relaxin and rosiglitazone induced signiﬁcant increases
in the expression levels of CD36 (Fig. 5A). The expression level of
LXR␣ was signiﬁcantly increased by rosiglitazone, and was also
increased by relaxin, although not to the point of statistical significance. To assess the effect of relaxin on cells naturally expressing
RXFP1, a similar experiment was performed in THP-1 cells, a
monocyte/macrophage cell line responsive to relaxin. Treatment
of THP-1 cells with relaxin signiﬁcantly increased the expression
of both CD36 and LXR␣ (Fig. 5B), similar to the response induced
by rosiglitazone.
3.3. Relaxin does not increase PPAR mRNA or protein levels
The relaxin effects on PPAR␥ activity did not require the addition
of exogenous PPAR␥ agonists, raising the possibility that relaxin
increased the expression or stability of PPAR␥. However, using
real-time RT-PCR, it was found that relaxin, rosiglitazone, or their
combination did not signiﬁcantly increase PPAR␥ mRNA in HEKRXFP1 cells (Fig. 6B). Likewise, no change was detectable in the

Fig. 4. Knockdown of PPAR␥ reduces the response to relaxin. PPAR␥-speciﬁc or
nontargeting control siRNA were introduced into HEK-RXFP1 cells by nucleofection.
(A) After 24 h, a portion of the cells were lysed and subject to Western blot analysis
to determine the levels of PPAR␥ or GAPDH. (B) The remaining cells were treated
with relaxin (1 nM), rosiglitazone (1 M), or vehicle for 24 h, then subject to the
PPRE luciferase assay. The data are expressed as the ACO-PPRE luciferase activity
relative to untreated cells, mean ± S.E.M. of six wells per condition. The experiment
was repeated three times, and a representative result is shown. *p < .05, **p < .001
compared with untreated control; †p < .001 compared to nontargeting siRNA under
the same treatment.

protein levels of PPAR␥ (Fig. 6A). Therefore, the increase in PPRE
transcriptional activity in response to relaxin in HEK-RXFP1 was
not due to increased expression or stability of PPAR␥.
3.4. Relaxin activation of PPAR is ligand-independent
Relaxin activation of PPAR␥ did not require exogenous PPAR␥
ligands, and did not increase PPAR␥ levels. Therefore, it is possible
that relaxin induces production of an endogenous PPAR␥ ligand, or
causes ligand-independent activation of PPAR␥. To address these
possibilities, a covalent modiﬁer of PPAR␥ that prevents ligand
binding (GW9662) was used to block ligand-dependent activation
of PPAR␥ transcriptional activity. As expected, PPAR␥ activation by
rosiglitazone was blocked by GW9662 (Fig. 7). In contrast, GW9662
had no effect on relaxin signaling, and only partially blocked the

Fig. 5. Relaxin increases the expression of PPAR␥ target genes. Cells were treated with 1 nM relaxin (Rlx) or 1 M rosiglitazone (Rosi) for 16 h. Total RNA was extracted, and
the mRNA for CD36 and LXR␣ were quantiﬁed by real-time RT-PCR, and normalized to the level of 18S rRNA using the relative CT method. The cell lines tested were (A)
HEK-RXFP1 cells, and (B) THP-1 monocytes. Data are expressed as the percent gene expression compared with untreated cells, mean ± S.E.M., N = 3. *p < .05 compared with
untreated cells.
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4. Discussion

Fig. 6. Relaxin does not increase PPAR␥ mRNA or protein. (A) HEK-RXFP1 cells were
treated with 1 nM relaxin (Rlx), 1 M rosiglitazone (Rosi), or both for 24 h. Total
protein was extracted and analyzed by Western blotting for PPAR␥ or GAPDH as
indicated. Blot shown is representative of at least four independent experiments. (B)
HEK-RXFP1 cells were treated with 1 nM relaxin (Rlx) or 1 M rosiglitazone (Rosi),
or both for 16 h. Total RNA was extracted, and the mRNA for PPAR␥ was quantiﬁed
by real-time RT-PCR, and normalized to the level of 18S rRNA using the relative CT
method. Data shown are mean ± S.E.M., N = 3.

combined effect of relaxin and rosiglitazone, reducing the response
to the level achieved by relaxin alone. Therefore, this data suggests
that relaxin does not increase the level of an endogenous PPAR␥ ligand in these cells, but may instead increase PPAR␥ activity through
a ligand-independent mechanism.

Fig. 7. Relaxin activation of PPAR␥ is not ligand-dependent. HEK-RXFP1 cells were
treated for 24 h with 1 nM relaxin (Rlx), 1 M rosiglitazone (Rosi), or both, in the
presence and absence of the inhibitor of PPAR␥ ligand binding (GW9662, 100 nM)
or vehicle control (DMSO) for 24 h, then subject to the PPRE luciferase assay. The data
are expressed as the ACO-PPRE luciferase activity relative to that of untreated cells,
mean ± S.E.M., N = 4. *p < .001 compared to untreated controls; #p < .01 compared to
GW9662 alone; †p < .05.

We have shown that relaxin activates transcriptional activity
through PPRE in cells expressing RXFP1. Despite the low expression levels of PPARs in these cells, relaxin consistently increased
activity through the PPRE reporter vector, with an efﬁcacy equal to
or greater than the PPAR␥ agonists. The relaxin effect was reduced
in the presence of dominant-negative PPAR␥, or by siRNA silencing. Finally, relaxin treatment resulted in increased expression of
the PPAR␥ target genes CD36 and LXR␣, both in cells overexpressing RXFP1 and cells naturally expressing the receptor. Therefore,
these are the ﬁrst experiments demonstrating activation of PPAR␥
transcriptional activity by relaxin.
The primary relaxin receptor is RXFP1, but potential alternative
receptors have been identiﬁed. Experiments in vitro have shown
that relaxin can also activate RXFP2, although the relevance of this
interaction has not been demonstrated in vivo, and InsL3 is the cognate ligand for RXFP2 (Bogatcheva et al., 2003; Hsu et al., 2002). In
some cells, relaxin can activate the glucocorticoid receptor, apparently in an RXFP1-independent manner (Dschietzig et al., 2005).
In our studies, PPAR␥ was activated in HEK-293T cells expressing RXFP1, but not in the untransfected cells that do not express
RXFP1 or RXFP2. The alternative RXFP1 ligand relaxin-3 also activated PPAR␥, but InsL3, which has extremely low afﬁnity for RXFP1,
had no effect. Therefore, the activation of PPAR␥ required the presence of RXFP1, and was not the result of action through alternative
relaxin receptors or glucocorticoid receptor activation.
The combination of relaxin and rosiglitazone caused a greater
increase in PPAR activity than either agent alone, suggesting that
they were acting through different mechanisms. Importantly, this
relaxin effect did not require the addition of exogenous PPAR␥
ligands. Therefore it was possible that relaxin was increasing the
expression of PPAR␥ or increasing the stability of PPAR␥ protein.
However, when PPAR␥ was overexpressed, the relaxin effect was
maintained. There was no change in PPAR␥ gene expression in
response to relaxin, and no increase in the levels of PPAR␥ protein. Another possible mechanism for relaxin activation of PPAR␥
activity could be increased production of an endogenous PPAR␥
ligand. Our data suggests that this is not the responsible mechanism. Treatment with GW9662, a covalent modiﬁer of PPAR␥
that prevents ligand-dependent activation, effectively blocked
rosiglitazone-induced PPAR␥. Conversely, the effect of relaxin was
not blocked by GW9662. If relaxin increased the production of an
endogenous ligand, then GW9662 should have blocked relaxin activation of PPAR␥. Therefore, other mechanisms may be responsible.
As stated above, the ability of relaxin to activate PPAR␥ did not
require the addition of exogenous PPAR␥ agonists. Furthermore,
unlike the results using the PPRE reporter vector, the expression of the PPAR␥ target genes CD36 and LXR␣ was greater in
response to rosiglitazone than to relaxin, providing further evidence that relaxin and rosiglitazone act on PPAR␥ through different
mechanisms. Together with the insensitivity to GW9662, the data
suggests that relaxin may be acting to stimulate PPAR␥ through
a ligand-independent mechanism, an area of increasing interest
(Xu and Li, 2008). In addition to its heterodimerization partner
RXR␣, PPAR␥ associates with a number of transcriptional coactivators and corepressors, which can regulate its activity and
speciﬁcity both in the absence and presence of PPAR␥ ligands (Feige
and Auwerx, 2007; Lonard and O’Malley, 2007; Puigserver and
Spiegelman, 2003). For example, PPAR␥ association with the coactivators PPAR␥ coactivator 1␣ (PGC1␣) or p300 results in increased
PPAR␥ ligand-independent transcriptional activity, and altered target gene speciﬁcity (Gelman et al., 1999; Puigserver et al., 1998).
In addition, the activity of PPAR␥, or its binding to coactivators
and corepressors can be regulated by phosphorylation (Burns and
Vanden Heuvel, 2007). Further study is needed to determine if

244

S. Singh, R.G. Bennett / Molecular and Cellular Endocrinology 315 (2010) 239–245

relaxin activation of PPAR␥ transcriptional activity involves one of
these mechanisms.
Through RXFP1, relaxin activates the cAMP pathway (Halls et al.,
2007; Sherwood, 2004). We have found that the EC50 for relaxinactivated PPAR␥ transcriptional activity was approximately 10-fold
lower than its ability to elevate cAMP levels. This ﬁnding raises the
possibility that relaxin activates PPAR␥ through additional signaling pathways. Indeed, relaxin has been shown to act through nitric
oxide, tyrosine kinase, and mitogen-activated protein kinase pathways (Anand-Ivell et al., 2007; Baccari and Bani, 2008; Dschietzig
et al., 2003; Mookerjee et al., 2009). Importantly, these same pathways have all been implicated in the regulation of PPAR␥ activity
(Burns and Vanden Heuvel, 2007; Lazennec et al., 2000; Ptasinska et
al., 2007). Indeed, there is considerable overlap in the properties of
relaxin and PPAR␥ in the response of ﬁbroblasts to ﬁbrotic stimuli.
For example, both relaxin and PPAR␥ agonists reduced the response
to the proﬁbrotic cytokine TGF␤ in skin (Unemori and Amento,
1990; Ghosh et al., 2004), lung (Burgess et al., 2005; Unemori et al.,
1996), and renal ﬁbroblasts (Masterson et al., 2004; Zaﬁriou et al.,
2005), and both agents have been effective in treatment of ﬁbrosis
in vivo (Samuel, 2005; Bennett, 2009; Michalik, 2006). Interestingly,
recent study provided evidence that in renal ﬁbroblasts, relaxin acts
to decrease the TGF␤-induced ﬁbrotic phenotype through multiple
mechanisms including cAMP, nitric oxide, and mitogen-activated
protein kinase (Mookerjee et al., 2009), providing further support
for cross-talk between relaxin and PPAR␥ signaling.
In summary, we have provided the ﬁrst evidence that relaxin
signaling through RXFP1 activates the transcriptional activity of
PPAR␥. These ﬁndings provide a possible mechanism for the antiﬁbrotic effects of relaxin. Because RXFP1 expression appears to be
lacking in glucoregulatory insulin-sensitive cells (Hsu et al., 2003;
Kamat et al., 2004), relaxin treatment may be an approach to the
treatment of ﬁbrosis by activation of PPAR␥, but without the glucoregulatory and adipogenic effects of thiazolidinediones and other
PPAR␥ agonists.
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